droperidol: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
droperidol: clinical details
Prescribing considerations
- Assess cardiac history, previous syncope, family history of congenital QT prolongation and concurrent QT-prolonging medicines.
- Check for bradycardia and correct hypokalaemia or hypomagnesaemia before use.
- Use particular caution with epilepsy, hepatic or renal impairment, older age, CNS depressants and medicines causing electrolyte loss.
- Consider additive sedation, respiratory depression and hypotension with perioperative medicines.
Contraindications and cautions
- Hypersensitivity to droperidol, an excipient or another butyrophenone
- Known or suspected QT prolongation, congenital long-QT syndrome or relevant family history
- Concomitant medicines known to cause torsades de pointes through QT prolongation
- Hypokalaemia or hypomagnesaemia
- Marked bradycardia or concurrent treatment known to cause bradycardia
- Phaeochromocytoma, coma, Parkinson’s disease or severe depression
Monitoring
- Review QTc, heart rate, electrolytes and interacting medicines in patients with relevant risk factors.
- Monitor blood pressure, consciousness, respiration and extrapyramidal effects after administration.
- Use continuous pulse oximetry when ventricular-arrhythmia risk is identified or suspected, as specified in the product information.
Clinical pharmacology
Droperidol is a butyrophenone with potent dopamine D2-receptor antagonism. After intravenous administration it acts rapidly, is highly protein-bound and undergoes extensive hepatic metabolism, mainly through CYP1A2 and CYP3A4; its metabolites lack neuroleptic activity.
Formulation and product differences
- The selected product is a clear, colourless intravenous solution supplied in single-use amber-glass ampoules and protected from light.
- It is essentially sodium-free and incompatible with barbiturates.
- After opening it is intended for immediate use; compatibility and handling requirements apply if prepared with morphine for patient-controlled analgesia.
droperidol preparations and strengths
Injection
Route: Parenteral
Strengths: 2.5 mg/mL
droperidol interactions
Important interactions include medicines that increase cardiac, sedative, movement-related or blood-pressure effects.
QT-prolonging medicines
Medicines such as amiodarone, sotalol, erythromycin, clarithromycin, haloperidol, domperidone and methadone can further increase the risk of torsades de pointes; specified combinations are contraindicated.
Metoclopramide and other neuroleptics
Combining dopamine-blocking medicines increases the likelihood of restlessness, muscle spasms and other extrapyramidal effects and should be avoided.
Opioids, benzodiazepines, barbiturates and alcohol
Sedation and central nervous system or respiratory depression may increase.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.